Polymorphic thiopurine methyltransferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia

Blood

Volumn 85, Issue 7, 1995, Pages 1897-1902

  McLeod, Howard L ^b   Relling, Mary V ^b   Liu, Qing ^b   Pui, Ching Hon ^b   Evans, William E ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; CYTARABINE; DIMETHYL SULFOXIDE; DITHIOTHREITOL; GLUTATHIONE; MERCAPTOPURINE; METHOTREXATE; S ADENOSYLMETHIONINE; TENIPOSIDE; THIOPURINE METHYLTRANSFERASE; TIOGUANINE; TROMETAMOL;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BLOOD TOXICITY; CHILD; CLINICAL ARTICLE; DIAGNOSTIC VALUE; DRUG BLOOD LEVEL; DRUG RESISTANCE; ENZYME ANALYSIS; ENZYME DEFICIENCY; FEMALE; GENETIC POLYMORPHISM; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; PROGNOSIS;

EID: 0028930908     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v85.7.1897.bloodjournal8571897     Document Type: Article

References (22)

1. Weinshilboum RM, Sladek SL: Mercaptopurine pharmacogenetics: Monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 32:651, 1980
2. McLeod HL, Lin J-S, Pui C-H, Scott EP, Evans WE: Thiopurine methyltransferase activity in American white subjects and black subjects. Clin Pharmacol Ther 55:15, 1994
3. Van Loon JA, Weinshilboum RM: Thiopurine methyltransferase biochemical genetics: Human lymphocyte activity. Biochem Genet 20:637, 1982
4. Szumlanski CL, Honchel R, Scott MC, Weinshilboum RM: Human liver thiopurine methyltransferase pharmacogenetics: Biochemical properties, liver-erythrocyte correlation and presence of isozymes. Pharmacogenetics 2:148, 1992
5. Elion GB: The purine path to chemotherapy. Science 244:41, 1989
6. Tay BS, Lilley R, McMurray AW, Atkinson MR: Inhibition of phosphoribosyl pyrophosphate amidotransferase for Erlich ascites tumor cells by thiopurine nucleotides. Biochem Pharmacol 18:936, 1969
7. Vogt MHJ, Stet EH, de Abreu RA, Bokkerink JPM, Lambooy LHJ, Trijbels FJM: The importance of methylthio-IMP for methy-mercaptopurine ribonucleoside cytotoxicity in Molt F4 human malignant T-lymphoblasts. Biochim Biophys Acta 1181:189, 1993
8. Lennard L, Lilleyman JS, Van Loon JA, Weinshilboum RM: Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 336:225, 1990
9. Evans WE, Horner MH, Chu YQ, Kalwinsky D, Roberts WM: Altered mercaptopurine metabolism, toxic effects and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. J Pediatr 119:985, 1991
10. McLeod HL, Miller DR, Evans WE: Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient. Lancet 1341:1151, 1993
11. Pui CH, Williams DL, Roberson PK, Raimondi SC, Behm FG, Lewis SH, Rivera GK, Kalwinsky DK, Abromowitch M, Crist WM: Correlation of karyotype and immunophenotype in childhood acute lymphoblastic leukemia. J Clin Oncol 6:56, 1988
12. Evans WE, Rodman J, Relling MV, Crom WR, Rivera GK, Crist WM, Pui C-H: Individualized dosages of chemotherapy as a strategy to improve response for acute lymphocytic leukemia. Semin Hematol 28:15, 1991 (suppl 4)
13. Weinshilboum RM, Raymond FA, Pazmino PA: Human erythrocyte thiopurine methyltransferase: Radiochemical microassay and biochemical properties. Clin Chim Acta 85:323, 1978
14. Evans WE, Relling MV: Clinical pharmacokinetics-pharmacodynamics of anticancer drugs. Clin Pharmacokinet 16:327, 1989
15. Lennard L, Lilleyman JS: Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia. J Clin Oncol 7:1816, 1989
16. Lilleyman JS, Lennard L: Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukaemia. Lancet 343:1188, 1994
17. Lennard L, Gibson BES, Nicole T, Lilleyman JS: Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukaemia. Arch Dis Child 69:577, 1993
18. Pieters R, Huismans DR, Loonen AH, Peters GJ, Hahlen K, van-der-Does-van-den-Berg A, van-Wering ER, Veerman AJ: Hypoxanthine-guanine phosphoribosyl-transferase in childhood leukemia: Relation with immunophenotype, in vitro drug resistance and clinical prognosis. Int J Cancer 51:213, 1992
19. Zimm S, Reaman G, Murphy RF, Poplack DG: Biochemical parameters of mercaptopurine activity in patients with acute lymphoblastic leukemia. Cancer Res 46:1495, 1986
20. Honchel R, Aksoy IA, Szumlanski C, Wood TC, Otterness DM, Wieben ED, Weinshilboum RM: Human thiopurine methyltransferase: Molecular cloning and expression of T84 colon carcinoma cell cDNA. Mol Pharmacol 43:878, 1993
21. Krynetski EY, Schuetz JD, Galpin AJ, Pui C-H, Relling MV, Evans WE: A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase. Proc Natl Acad Sci USA 1995 (in press)
22. Bostrom B, Erdmann GR: Cellular pharmacology of 6-mercaptopurine in acute lymphoblastic leukemia. Am J Ped Hematol Oncol 15:80, 1993